SHR-8068 combined with adebrelimab and bevacizumab in the treatment of refractory advanced colorectal cancer: study protocol for a single-arm, phase Ib/II study
This proof-of-concept study would provide safety and efficacy signals of this novel combination treatment for the MSS CRCs in the late-line setting. And it may offer new insights on the clinical application of dual immunotherapy combined with anti-angiogenic therapy in the MSS CRC.
Authors
- Jianfei Wang (ORCID: https://orcid.org/0000-0003-1575-4473)
- Xin Wang (ORCID: https://orcid.org/0000-0001-9325-3194)
- Pei Zhang (ORCID: https://orcid.org/0000-0002-5216-335X)
- Xiaofen Li (ORCID: https://orcid.org/0000-0002-2079-9038)
- Yu Yang
- Dan Cao
Institutions
- Sichuan University (CN)
- Jiangsu Hengrui Medicine (China) (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-10-09
- DOI
- https://doi.org/10.3389/fimmu.2024.1450533
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Sichuan University
- West China Hospital, Sichuan University